Future possibilities in glaucoma therapy

Medical Science Monitor

Volumn 16, Issue 11, 2010, Pages 252-259

  Wierzbowska, Joanna ^a   Robaszkiewicz, Jacek ^a   Figurska, MaŁgorzata ^a   Stankiewicz, Andrzej ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Glaucoma; Open angle drug therapy; Trabecular meshwork drug effects

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AMINOGUANIDINE; AR 102; BLEBBISTATIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BUTAPROST; CALCIUM CHANNEL BLOCKING AGENT; CALDESMON; CYTOCHALASIN B; DE 104; DORZOLAMIDE; FASUDIL; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; ILOMASTAT; K 115; LATANOPROST; LATRUNCULIN B; MEMANTINE; N (2 AMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; SNJ 1656; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y 39983; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ADENOVIRUS VECTOR; ANECORTAVE; ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; CEFTRIAXONE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIFEPRISTONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOLADIN; PARVOVIRUS VECTOR; PILOCARPINE; TIMOLOL MALEATE; UBIDECARENONE; NEUROPROTECTIVE AGENT; PROSTAGLANDIN DERIVATIVE;

APOPTOSIS; AXONAL INJURY; BLOOD BRAIN BARRIER; CELL ADHESION; CELL JUNCTION; CILIARY BODY EPITHELIUM; CLINICAL EVALUATION; CONJUNCTIVA; CYTOSKELETON; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; GENE THERAPY; GLAUCOMA; HUMAN; IMMUNOTHERAPY; INTRAOCULAR PRESSURE; MEDLINE; MESENCHYMAL STEM CELL; MUELLER CELL; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; RETINA CELL; RETINA GANGLION CELL; REVIEW; TRABECULAR MESHWORK; TREATMENT PLANNING; AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GLAUCOMA SURGERY; MESENCHYMAL STEM CELL TRANSPLANTATION; OPTIC NERVE LESION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; AQUEOUS HUMOR; CELL DEATH; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANIMALS; AQUEOUS HUMOR; CELL DEATH; GENE THERAPY; GLAUCOMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; PROSTAGLANDINS, SYNTHETIC; RETINAL GANGLION CELLS; TRABECULAR MESHWORK;

EID: 79951559421     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Goldberg I: Glaucoma in the 21st century. Asian J Ophthalmol, 2000; 3: 12-14.
2. Guo G, Bhat NR: Hypoxia/reoxygenation differentially modulates NF-kappa activation and iNOS expression in astrocytes and microglia. Antioxid Redox Signal, 2006; 8: 911-18.
3. Golubnitschaja O, Yeghiazaryan K, Liu R et al: Increased expression of matrix metalloproteinases in mononuclear blond cells of normal tension glaucoma patients. J Glaucoma, 2004; 13: 66-72.
4. Flammer J, Mozaffarieh M: What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol, 2007; 52(Suppl.2): S162-73.
5. Harris A, Zarfati D, Zalish M et al: Reduced cerebrovascular blood flow velocities and vasoreactivity in open-angle glaucoma. Am J Ophthalmol, 2003; 135: 144-47.
6. Plange N, Remky A, Arend O: Colour Doppler imaging and fluorescein filling defects of the optic disc in normal tension glaucoma. Br J Ophthalmol, 2003; 87: 731-36.
7. Harris A, Werne A, Cantor LB: Vascular abnormalities in glaucoma: from population-based studies to the clinic? Am J Ophthalmol, 2008; 145: 595-97.
8. Gherghel D, Hosking SL, Cunliffe IA: Abnormal systemic and ocular vascular response to temperature provocation in primary open-angle glaucoma patients: a case for autonomic failure? Invest Ophthalmol Vis Sci, 2004; 45: 3546-54.
9. Hamard P, Hamard H, Dufaux J, Quesnot S: Optic nerve head blood flow using a laser Doppler velocimeter and haemorheology in primary open angle glaucoma and normal pressure glaucoma. Br J Ophthalmol, 1994; 78: 449-53.
10. Luthra A, Gupta N, Kaufman PL et al: Oxidative injury by peroxynitrite in neural and vascular tissue of the lateral geniculate nucleus in experimental glaucoma. Exp Eye Res, 2005; 80: 43-49.
11. Gupta N, Ang LC, Noël de Tilly L et al: Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol, 2006; 90: 674-78.
12. Lütjen-Drecoll E: Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res, 2005; 81: 1-4.
13. Wordinger RJ, Agarwal R, Talati M et al: Expression of bone morphogenetic proteins (BMP), BMP receptors, and BMP associated proteins in human trabecular meshwork and optic nerve head cells and tissues. Mol Vis, 2002; 8: 241-50.
14. Armaly MF, Krueger DE, Maunder L et al: Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol, 1980; 98: 2163-71.
15. Shiose Y, Kitazawa Y, Tsukahara S: Epidemiology of glaucoma in Japan - a nationwide glaucoma survey. Jpn J Ophthalmol, 1991; 35: 133-55.
16. Steele RM, Benedini F, Biondi S et al: Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett, 2009; 19: 6565-70.
17. Nilsson SF, Drecoll E, Lütjen-Drecoll E et al: The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci, 2006; 47: 4042-49.
18. Gabelt BT, Okka M, Dean TR, Kaufman PL: Aqueous humor dynamics in monkeys after topical R-DOI. Invest Ophthalmol Vis Sci, 2005; 46: 4691-96.
19. Kaufman PL, Svedbergh B, Lütjen-Drecoll E: Medical trabeculocanalotomy in monkeys with cytochalasin B or EDTA. Ann Ophthalmol, 1979; 11: 795-96.
20. Fukata Y, Amano M, Kaibuchi K: Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganisation of non-muscle cells. Trends Pharmacol Sci, 2001; 22: 32-39.
21. Honjo M, Tanihara H, Inatani M et al: Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci, 2001; 42: 137-44.
22. Rao PV, Deng PF, Kumar J, Epstein DL: Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci, 2001; 42: 1029-37.
23. Tian B, Kaufman PL: Effect of the Rho-kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res, 2005; 80: 215-25.
24. Epstein DL, Rowlette LL, Roberts BC: Acto-Myosin Drug Effects and Aqueous Outflow Function. Invest Ophthalmol Vis Sci, 1999; 40: 74-81.
25. Tian B, Kaufman PL, Volberg T, Gabelt BT, Geiger B: H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol, 1998; 116: 633-43.
26. Tian B, Geiger B, Epstein DL, Kaufman PL: Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci, 2000; 41: 619-23.
27. Tian B, Brumback LC, Kaufman PL: ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey. Exp Eye Res, 2000; 71: 551-66.
28. Rao PV, Deng PF, Sasaki Y, Epstein DL: Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility. Exp Eye Res, 2005; 80: 197-206.
29. Thieme H, Nuskovski M, Nass JU et al: Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci, 2000; 41: 4240-46.
30. Tian B, Gabelt BT, Kaufman PL: Effect of staurosporine on outflow facility in monkeys. Invest Ophthalmol Vis Sci, 1999; 40: 1009-11.
31. Honjo M, Inatani M, Kido N et al: A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res, 2002; 75: 135-42.
32. Zhang M, Rao PV: Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci, 2005; 46: 4130-38.
33. Ethier CR, Read AT, Chan DW: Effects of Latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest Ophthalmol Vis Sci, 2006; 47: 1991-98.
34. Johnson DH: The Effect of Cytochalasin D on Outflow Facility and the Trabecular Meshwork of the Human Eye in Perfusion Organ Culture. Invest Ophthalmol Vis Sci, 1997; 38: 2790-99.
35. Song J, Deng PF, Stinnett SS et al: Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci, 2005; 46: 2424-32.
36. Straiker AJ, Maguire G, Mackie K, Lindsey J: Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci, 1999; 40: 2442-48.
37. Zhong L, Geng L, Njie Y et al: CB2 Cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci, 2005; 46: 1988-92.
38. Njie YF, Kumar A, Qiao Z et al: Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol Vis Sci, 2006; 47: 1999-2005.
39. Robin AL, Clark AF, Covert DW et al: Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol, 2009; 147: 45-50.
40. Clark RD: Glucocorticoid receptor antagonists. Curr Top Med Chem, 2008; 8: 813-38.
41. Neufeld AH, Sawada A, Becker B: Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA, 1999; 96: 9944-48.
42. Manabe S, Gu Z, Lipton SA: Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci, 2005; 46: 4747-53.
43. Hara H, Toriu N, Shimazawa M: Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev, 2004; 22: 199-214.
44. Koseki N, Araie M, Tomidokoro A et al: A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology, 2008; 115: 2049-57.
45. Cheung W, Guo L, Cordeiro MF: Neuroprotection in glaucoma. Optom Vis Sci, 2008; 85: 406-16.
46. Kitazawa Y, Shirai H, Go FJ: The effect of Ca2(+)-antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol, 1989; 227: 408-12.
47. Rothstein JD, Patel S, Regan MR et al: b-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005; 433: 73-77.
48. Tatton WG, Chalmers-Redman RM, Sud A et al: Maintaining mitochondrial membrane impermeability an opportunity for new therapy in glaucoma? Surv Ophthalmol, 2001; 45(Suppl.3): S277-83.
49. Tezel G, Yang X: Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sc, 2004; 45: 4049-59.
50. Abu-Amero KK, Morales J, Bosley TM: Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci, 2006; 47: 2533-41.
51. Zamora M, Meroño C, Viñas O, Mampel T: Recruitment of NF-kappaB into mitochondria is involved in adenine nucleotide translocase 1 (ANT1)-induced apoptosis. J Biol Chem, 2004; 279: 38415-23.
52. Cordeiro MF, Guo L, Cheung W et al: Topical CoQ10 is neuroprotective in experimental glaucoma [abstract]. Invest Ophthalmol Vis Sci, 2007; 48E-Abstract 4369.
53. Ishii Y, Kwong JM, Caprioli J: Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci, 2003; 44: 1982-92.
54. Uchida S, Fujiki M, Nagai Y et al: Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to neuroprotection against cerebral infarction in rats. Neurosci Lett, 2006; 396: 220-24.
55. Guo L, Salt TE, Luong V et al: Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA, 2007; 104: 13444-49.
56. Nickells RW: From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol, 2007; 42: 278-87.
57. Chong ZZ, Lin SH, Kang JQ, Maiese K: Erythropoietin prevents early and late neural demise through modulation of Akt1 and induction of caspase 1, 3 and 8. J Neurosci Res, 2003; 71: 659-69.
58. Zalewska R, Zalewski B, Reszec J et al: The expressions of Fas and caspase- 3 in human glaucomatous optic nerve axons. Med Sci Monit, 2008; 14(12): BR274-78.
59. Borrás T, Brandt CR, Nickells R, Ritch R: Gene therapy for glaucoma: treating a multifaceted, chronic disease. Invest Ophthalmol Vis Sci, 2002; 43: 2513-18.
60. Kee C, Sohn S, Hwang JM: Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci, 2001; 42: 2856-60.
61. Vittitow JL, Garg R, Rowlette LL: Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis, 2002; 8: 32-44.
62. Wordinger RJ, Fleenor DL, Hellberg PE et al: Effects of TGF-beta2, BMP- 4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci, 2007; 48: 1191-200.
63. Fuchshofer R, Yu AH, Welge-Lüssen U, Tamm ER: Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci, 2007; 48: 715-26.
64. Grosheva I, Vittitow JL, Goichberg P et al: Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells. Exp Eye Res, 2006; 82: 945-58.
65. Santas AJ, Bahler C, Peterson JA et al: Effect of Heparin II Domain of Fibronectin on Aqueous Outflow in Cultured Anterior Segments of Human Eyes. Invest Ophthalmol Vis Sci, 2003; 44: 4796-804.
66. Bertazolli-Filho R, Ghosh S, Huang W: Molecular evidence that human ocular ciliary epithelium expresses components involved in phototransduction. Biochem Biophys Res Commun, 2001; 284: 317-25.
67. Zhang D, Vetrivel L, Verkman AS: Aquaporin deletion in mice reduces intraocular pressure and aqueous fluid production. J Gen Physiol, 2002; 119: 561-69.
68. Barraza RA, McLaren JW, Poeschla EM: Prostaglandin Pathway Gene Therapy for Sustained Reduction of Intraocular Pressure. Mol Ther, 2010; 18(3): 491-501.
69. Martin KR, Quigley HA, Zack DJ et al: Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci, 2003; 44: 4357-65.
70. Cheng L, Sapieha P, Kittlerova P et al: TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci, 2002; 22: 3977-86.
71. Perkins TW, Faha B, Kiland J et al: Effect of P21 gene therapy of glaucoma filtering surgery in rabbits [ARVO Abstract]. Invest Ophthalmol Vis Sci, 2000; 41: S580. Abstract nr 3082.
72. Angella GJ, Sherwood MB, Balasubramanian L et al: Enhanced shortterm plasmid transfection of filtration surgery tissues. Invest Ophthalmol Vis Sci, 2000; 41: 4158-62.
73. Borrás T, Gabelt BT, Klintworth GK et al: Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med, 2001; 3: 437-49.
74. Kee C, Sohn S, Hwang JM: Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci, 2001; 42: 2856-60.
75. Hangai M, Tanihara H, Honda Y, Kaneda Y: Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest Ophthalmol Vis Sci, 1998; 39: 509-16.
76. Stechschulte SU, Joussen AM, von Recum HA et al: Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci, 2001; 42: 1975-79.
77. Wang F, Qi LX, Su Y et al: S phase kinase-interacting protein 2 targeting SiRNA inhibits cell proliferation of tenon's capsule fibroblast by increasing p27 protein level. Invest Ophthalmol Vis Sci, 2010; 51(3): 1475-82.
78. Sieving PA, Caruso RC, Tao W et al: Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA, 2006; 103: 3896-901.
79. Sakai T, Kuno N, Takamatsu F et al: Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest Ophthalmol Vis Sci, 2007; 48: 3381-87.
80. Jiang C, Moore MJ, Zhang X et al: Intravitreal injections of GDNFloaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis, 2007; 13: 1783-92.
81. Park DH, Eve DJ: Regenerative medicine: advances in new methods and technologies. Med Sci Monit, 2009; 15(11): RA233-51.
82. Bull ND, Limb GA, Martin KR: Human Müller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci, 2008; 49: 3449-56.
83. Shimizu K, Ito A, Honda H: Enhanced cell-seeding into 3D porous scaffolds by use of magnetite nanoparticles. J Biomed Mater Res B Appl Biomater, 2006; 77: 265-72.
84. Meyer JS, Katz ML, Maruniak JA, Kirk MD: Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cells, 2006; 24: 274-83.
85. Bull ND, Irvine KA, Franklin RJ, Martin KR: Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci, 2009; 50: 4244-53.
86. Alberti E, Los M, García R et al: Prolonged survival and expression of neural markers by bone marrow-derived stem cells transplanted into brain lesions. Med Sci Monit, 2009; 15(2): BR47-54.
87. Wiggs JL: Genetic etiologies of glaucoma. Arch Ophthalmol, 2007; 125: 30-37.
88. Fingert JH, Héon E, Liebmann JM et al: Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet, 1999; 8: 899-905.
89. Alward WL, Kwon YH, Kawase K et al: Evaluation of optineurin sequence variations in 1.048 patients with open-angle glaucoma. Am J Ophthalmol, 2003; 136: 904-10.
90. Libby RT, Smith RS, Savinova OV et al: Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science, 2003; 299: 1578-81.
91. Charlesworth JC, Dyer TD, Stankovich JM et al: Linkage to 10q22 for maximum intraocular pressure and 1p32 for maximum cup-to-disc ratio in an extended primary open-angle glaucoma pedigree. Invest Ophthalmol Vis Sci, 2005; 46: 3723-29.
92. Duggal P, Klein AP, Lee KE et al: Identification of novel genetic loci for intraocular pressure: a genomewide scan of the Beaver Dam Eye Study. Arch Ophthalmol, 2007; 125: 74-79.
93. Rotimi CN, Chen G, Adeyemo AA et al: Genomewide scan and fine mapping of quantitative trait loci for intraocular pressure on 5q and 14q in West Africans. Invest Ophthalmol Vis Sci, 2006; 47: 3262-67.
94. Wiggs JL, Allingham RR, Hossain A et al: Genome-wide scan for adult onset primary open angle glaucoma. Hum Mol Genet, 2000; 9: 1109-17.
95. Vincent AL, Billingsley G, Buys Y et al: Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. Am J Hum Genet, 2002; 70: 448-60.
96. Nemesure B, Jiao X, He Q et al: A genome-wide scan for primary openangle glaucoma (POAG): the Barbados Family Study of Open-Angle Glaucoma Hum Genet, 2003; 112: 600-9.
97. Shastry BS: Pharmacogenetics and the concept of individualized medicine Pharmacogenomics J, 2006; 6: 16-21.
98. Abramowicz ME: AmpliChip CYP450 test. Med Lett Drugs Ther, 2005; 47: 71-72.
99. Bruno C, Fisher G, Moroi S: Is "scarless wound healing" applicable to glaucoma surgery? Expert Rev Ophthalmol, 2007; 2: 79-90.
100. Jiang J, Gill HS, Ghate D et al: Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci, 2007; 48: 4038-43.
101. Patil S, Reshetnikov S, Haldar MK et al: Surface-Derivatized Nanoceria with Human Carbonic Anhydrase II Inhibitors and Fluorophores: A Potential Drug Delivery Device. J Phys Chem, 2007; 111: 8437-42.
102. Bawa P, Pillay V, Choonara YE, du Toit LC: Stimuli-responsive polymers and their applications in drug delivery. Biomed Mater, 2009; 4: 22001.
103. Ammar HO, Salama HA, Ghorab M, Mahmoud AA: Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech, 2009; 10: 808-19.
104. Schultz CL, Poling TR, Mint JO: A medical device/drug delivery system for treatment of glaucoma Clin Exp Optom, 2009; 92: 343-48.
105. Polak MB, Valamanesh F, Felt O et al: Controlled delivery of 5-chlorouracil using poly(ortho esters) in filtering surgery for glaucoma. Invest Ophthalmol Vis Sci, 2008; 49: 2993-3003.